ATE515506T1 - Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren - Google Patents

Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren

Info

Publication number
ATE515506T1
ATE515506T1 AT08708929T AT08708929T ATE515506T1 AT E515506 T1 ATE515506 T1 AT E515506T1 AT 08708929 T AT08708929 T AT 08708929T AT 08708929 T AT08708929 T AT 08708929T AT E515506 T1 ATE515506 T1 AT E515506T1
Authority
AT
Austria
Prior art keywords
synthesis
kinase inhibitors
aminothiazole compounds
aminothiazole
compounds
Prior art date
Application number
AT08708929T
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
Francois Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Application granted granted Critical
Publication of ATE515506T1 publication Critical patent/ATE515506T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT08708929T 2007-02-13 2008-02-13 Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren ATE515506T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE515506T1 true ATE515506T1 (de) 2011-07-15

Family

ID=39332208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08708929T ATE515506T1 (de) 2007-02-13 2008-02-13 Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren

Country Status (23)

Country Link
US (3) US8153792B2 (de)
EP (2) EP2366703B1 (de)
JP (2) JP5568312B2 (de)
KR (1) KR20090110851A (de)
CN (2) CN101657446B (de)
AR (1) AR065337A1 (de)
AT (1) ATE515506T1 (de)
AU (1) AU2008214679A1 (de)
BR (1) BRPI0807626B1 (de)
CA (2) CA2677586C (de)
ES (2) ES2522169T3 (de)
HR (2) HRP20110709T1 (de)
IL (1) IL200320A0 (de)
MA (1) MA31180B1 (de)
MX (1) MX2009008665A (de)
NZ (1) NZ578944A (de)
PL (2) PL2366703T3 (de)
RU (2) RU2456285C2 (de)
SI (2) SI2118099T1 (de)
TN (1) TN2009000342A1 (de)
TW (1) TWI406862B (de)
WO (1) WO2008098949A2 (de)
ZA (1) ZA200905981B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
PT1525200E (pt) 2002-08-02 2008-01-10 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças
AR080048A1 (es) 2010-01-28 2012-03-07 Ab Science Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib
AR080096A1 (es) 2010-02-01 2012-03-14 Ab Science Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
WO2011131705A1 (en) 2010-04-20 2011-10-27 Ab Science Treatment of multiple sclerosis with masitinib
WO2011151372A1 (en) 2010-06-02 2011-12-08 Ab Science Treatment of rheumatoid arthritis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
US20140147415A1 (en) 2010-11-05 2014-05-29 Ab Science Treatment of mastocytosis with masitinib
WO2012104402A1 (en) * 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
AR085934A1 (es) 2011-04-08 2013-11-06 Ab Science Tratamiento de mieloma multiple con masitinib
BR112015007144A2 (pt) 2012-10-04 2017-12-12 Ab Science uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
WO2015082496A1 (en) 2013-12-02 2015-06-11 Ab Science Use of masitinib for treatment of colorectal cancer
EP2886543A1 (de) 2013-12-18 2015-06-24 Sandoz Ag Kristalline Form von Masitinib
WO2015185958A1 (en) 2014-06-02 2015-12-10 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
CN106794179A (zh) * 2015-07-29 2017-05-31 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
CA3000894A1 (en) 2015-10-05 2017-04-13 Ab Science Treatment of severe systemic mastocytosis with masitinib
ES2899929T3 (es) 2016-03-25 2022-03-15 Ab Science Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica
WO2018177854A1 (en) 2017-03-31 2018-10-04 Sandoz Ag Crystalline form of masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2021099616A1 (en) 2019-11-22 2021-05-27 Ab Science Masitinib for the treatment of sickle cell disease
EP3831384A1 (de) 2019-12-02 2021-06-09 AB Science Verwendung von masitinib zur behandlung von eosinophilem asthma
KR20220143020A (ko) 2020-02-20 2022-10-24 에이비 사이언스 다발 경화증 환자 하위집단의 치료를 위한 마시티닙
IL297021A (en) 2020-04-10 2022-12-01 Ab Science Use of masitinib to treat the 2019 coronavirus disease (covid-19)
JP2023554354A (ja) 2020-12-16 2023-12-27 エービー サイエンス アルツハイマー病の処置のためのマシチニブ
KR20240008875A (ko) 2021-05-17 2024-01-19 에이비 사이언스 거세-저항성 전립선암의 치료를 위한 마시티닙
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
EP0983260A2 (de) * 1997-05-22 2000-03-08 G.D. Searle & Co. 4-aryl-3 (5)-heteroaryl substituierte pyrazole als inhibitoren der p38 kinase
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
SK5212000A3 (en) * 1997-10-27 2001-04-09 Agouron Pharmaceuticals Inc Ag 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
HUP0202682A3 (en) * 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
EP1401413B1 (de) 2001-06-29 2006-11-22 AB Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
WO2003002105A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
WO2003002107A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
CA2452171A1 (en) 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004536097A (ja) 2001-06-29 2004-12-02 アブ サイエンス 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法
EP1401412A2 (de) 2001-06-29 2004-03-31 AB Science Verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von tumorangiogenese
EP1461032B1 (de) 2001-09-20 2008-07-16 AB Science Die verwendung von c-kithemmern zur förderung des haarwuchses
CA2461181A1 (en) 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
WO2003039550A1 (en) 2001-09-20 2003-05-15 Ab Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
US20050203098A1 (en) 2002-02-27 2005-09-15 Alain Moussy Use of tyrosine kinase inhibitors for treating substance use disorders
ATE334693T1 (de) 2002-02-27 2006-08-15 Ab Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
PL373842A1 (en) * 2002-05-29 2005-09-19 Amgen Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
PT1525200E (pt) * 2002-08-02 2008-01-10 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
CA2515215A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2517308A1 (en) 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
CN1860118A (zh) * 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EP1653934B1 (de) 2003-08-15 2008-05-14 AB Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
CA2551529C (en) * 2003-12-25 2011-02-01 Nippon Shinyaku Co., Ltd. Amide derivative and medicine
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
HRP20110709T1 (hr) 2011-11-30
CN103342701A (zh) 2013-10-09
EP2366703B1 (de) 2014-07-30
ES2369617T3 (es) 2011-12-02
EP2118099A2 (de) 2009-11-18
US20120196871A1 (en) 2012-08-02
JP5568312B2 (ja) 2014-08-06
HRP20140986T1 (hr) 2014-11-21
WO2008098949A2 (en) 2008-08-21
SI2118099T1 (sl) 2011-11-30
US8940894B2 (en) 2015-01-27
PL2366703T3 (pl) 2015-02-27
CN103342701B (zh) 2016-09-21
TW200848419A (en) 2008-12-16
US20130289045A1 (en) 2013-10-31
CA2677586C (en) 2017-07-25
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
RU2009132186A (ru) 2011-03-20
PL2118099T3 (pl) 2011-12-30
EP2366703A1 (de) 2011-09-21
BRPI0807626B1 (pt) 2022-03-03
CA2677586A1 (en) 2008-08-21
CN101657446A (zh) 2010-02-24
BRPI0807626A2 (pt) 2014-11-25
CA2970628C (en) 2019-08-27
IL200320A0 (en) 2010-04-29
MX2009008665A (es) 2009-08-21
WO2008098949A3 (en) 2008-10-02
JP2013177437A (ja) 2013-09-09
CA2970628A1 (en) 2008-08-21
JP2010518141A (ja) 2010-05-27
KR20090110851A (ko) 2009-10-22
ZA200905981B (en) 2010-11-24
ES2522169T3 (es) 2014-11-13
CN101657446B (zh) 2013-05-15
SI2366703T1 (sl) 2014-10-30
AU2008214679A1 (en) 2008-08-21
TN2009000342A1 (en) 2010-12-31
TWI406862B (zh) 2013-09-01
RU2456285C2 (ru) 2012-07-20
US8153792B2 (en) 2012-04-10
RU2491286C1 (ru) 2013-08-27
EP2118099B1 (de) 2011-07-06
AR065337A1 (es) 2009-06-03
NZ578944A (en) 2011-03-31
US8492545B2 (en) 2013-07-23
JP5784073B2 (ja) 2015-09-24

Similar Documents

Publication Publication Date Title
ATE515506T1 (de) Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren
ATE538111T1 (de) Verfahren zur synthese von 5- alkoxymethylfurfuralethern
ATE474845T1 (de) Verfahren zur synthese von saccharose-6-estern
ATE459416T1 (de) Verfahren zur beseitigung von endokrin wirksamen verbindungen
HK1259148A1 (zh) 用作atr激酶抑制劑的化合物
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
ATE540931T1 (de) Verfahren zur synthese organischer verbindungen
SMT201600267B (it) Inibitori di syk imidazopirazinici
DE602008004764D1 (de) Verfahren zur hydrokonversion von schwerölen
SI2021335T1 (sl) Heterocikliäśne spojine kot zaviralci c-fms kinaze
ATE554078T1 (de) Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
DE602006014670D1 (de) Verfahren zur doppelbindungs-hydroisomerisierung von butenen
HK1161260A1 (zh) 用作 激酶抑制劑的化合物
SMT201400133B (it) Composti e composizioni come inibitori di protein chinasi
ATE551342T1 (de) Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
ATE487709T1 (de) Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)benzolamin
ATE486853T1 (de) Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK2257532T3 (da) Fremgangsmåde til regioselektiv syntese af 1-alkyl-3-haloalkyl-pyrazol-4-carboxylsyrederivater
ATE478849T1 (de) 4-anilinochinolin-3-carbonsäureamide als csf-1r- kinaseinhibitoren
DE602007008201D1 (de) Verfahren zur qualitätskontrolle von speichermedien
DE602005024305D1 (de) Verfahren zu synthese von glycolonitril
ATE460408T1 (de) Verfahren zur synthese von strontiumranelat und seinen hydraten
ATE483690T1 (de) Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)-benzeneamin
DE112009001327A5 (de) Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties